Aura Biosciences is a technology company.
Aura Biosciences has raised $131.0M across 3 funding rounds.
Aura Biosciences has raised $131.0M in total across 3 funding rounds.
Aura Biosciences is a clinical-stage biotechnology company developing precision therapies for solid tumors using its proprietary virus-like drug conjugate (VDC) platform, focusing on high unmet needs in ocular and urologic cancers.[1][2][3][7] Its lead product, belzupacap sarotalocan (bel-sar or AU-011), targets early-stage choroidal melanoma in a global Phase 3 CoMpass trial under FDA Special Protocol Assessment, with additional exploration in choroidal metastases, ocular surface cancers, and non-muscle invasive bladder cancer (NMIBC).[3][9] The company serves oncology patients needing organ-preserving treatments, addressing limited options in these rare cancers affecting over 60,000 annually in the US and Europe, and shows growth momentum as a publicly listed entity (NASDAQ: AURA) with ongoing late-stage trials, orphan drug designations, and recent patent filings.[1][3]
Aura Biosciences emerged from innovative research into virus-like particle-drug conjugates (VDC) to tackle underserved oncology areas, with early investment from Advent Life Sciences in its 2015 Series B round led by CEO Elisabet de los Pinos.[1] The company advanced its pipeline rapidly, dosing the first patient in a Phase 2 suprachoroidal study for choroidal melanoma and presenting Phase 1b/2 data at key conferences like the Macula Society and AAO meetings.[5][6] Pivotal moments include interim Phase 2 data in 2022 showing efficacy in early-stage choroidal melanoma, preclinical support for choroidal metastasis at ARVO 2022, and progression to Phase 3 CoMpass trial design announcement, marking its evolution into a late-stage biotech headquartered in Boston.[1][3]
Aura Biosciences rides the wave of targeted oncology therapies and precision medicine, particularly in rare solid tumors where surgery or radiation risks vision loss or organ damage, aligning with trends in immune-ablative and virus-based conjugates.[7][8] Timing is ideal amid rising focus on ocular oncology (e.g., choroidal melanoma's poor prognosis without effective non-invasive options) and urologic cancers like NMIBC, bolstered by regulatory fast tracks and a market need for >60,000 annual cases.[3] Favorable forces include biotech investor interest in platform technologies with multi-indication potential and advancements in suprachoroidal delivery for eye diseases; Aura influences the ecosystem by pioneering VDC for organ-sparing treatments, potentially setting standards for similar rare cancers.[1][2][9]
Aura's path forward centers on CoMpass Phase 3 topline data, potential regulatory filings for bel-sar in choroidal melanoma, and Phase 1/2 expansion in NMIBC and other ocular indications, with new patents securing long-term IP.[3] Trends like AI-driven trial enrichment, combination immunotherapies, and global orphan drug incentives will shape its trajectory, positioning it to evolve from clinical-stage player to commercial oncology leader transforming patient outcomes in underserved areas. This builds on its VDC platform's promise as the first targeted therapy for ocular melanoma, delivering precision where it's needed most.[1][3][7]
Aura Biosciences has raised $131.0M in total across 3 funding rounds.
Aura Biosciences's investors include Forbion, Sanofi Ventures, Versant Ventures, Ysios Capital, Arix Bioscience.
Aura Biosciences has raised $131.0M across 3 funding rounds. Most recently, it raised $80.0M Venture Round in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $80.0M Venture Round | Forbion, Sanofi Ventures, Versant Ventures, Ysios Capital | |
| Dec 1, 2017 | $30.0M Series C | Arix Bioscience, Forbion, Sanofi Ventures, Versant Ventures, Ysios Capital | |
| Mar 1, 2015 | $21.0M Series B | Forbion, Sanofi Ventures, Versant Ventures, Ysios Capital |